Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander James Thompson

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Current Gastroenterology Reports|April 29, 2010
Antifibrotic therapies: will we ever get there?Alexander James Thompson, Keyur Patel
Pharmacoeconomics|March 18, 2020
A Comparison of the EQ-5D-3L and EQ-5D-5LAlexander James Thompson, Alex James Turner
World Journal of Gastroenterology|March 30, 2016
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1Ira Jacobson, Stefan Zeuzem, Robert Flisiak, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Current Gastroenterology Reports|April 29, 2010
Antifibrotic therapies: will we ever get there?Alexander James Thompson, Keyur Patel
Pharmacoeconomics|March 18, 2020
A Comparison of the EQ-5D-3L and EQ-5D-5LAlexander James Thompson, Alex James Turner
World Journal of Gastroenterology|March 30, 2016
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1Ira Jacobson, Stefan Zeuzem, Robert Flisiak, et al.
Pageof 1